Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

New all-oral regimen improves treatment convenience for AML patients

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.

3 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Loss of X chromosome linked to female infertility risk

Chromosomes carry genetic information for biological sex, which generally assigns women two X chromosomes and men XY chromosomes.

12 May 2026

Diverse leukemia stem cells may drive AML relapse after therapy

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).

7 May 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Early life exposure to PFAS associated with common childhood leukemia

Early exposure to PFAS, a group of widely used compounds known as "forever chemicals," was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to University of California, Irvine Joe C. Wen School of Population & Public Health researchers.

27 Apr 2026

New strategy boosts natural killer cells to fight cancer

Scientists have developed a strategy to boost the cancer-fighting power of natural killer (NK) cells, part of the immune system's first line of defense.

24 Apr 2026

New target CD43 may improve leukemia immunotherapy outcomes

Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.

11 Apr 2026

Study finds increasing rates of therapy-related acute myeloid leukemia

Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood.

6 Apr 2026

Fertility treatments linked to small increases in some cancers

Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns with the general female population.

13 Mar 2026

Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

11 Feb 2026

New study exposes a targetable vulnerability in acute myeloid leukemia

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway involved in the body's inflammation response.

19 Jan 2026

Newly identified rare genetic variant reduces the risk of leukemia

A newly identified and rare genetic variant slows the growth of mutated blood stem cells, researchers report, and it reduces the risk of leukemia.

2 Jan 2026

Combination therapy offers hope for AML patients facing drug resistance

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.

30 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation.

12 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025